2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 101–200 of 2,029
Bracco, P. A., Reichelt, A. J., Alves, L. F., Vidor, P. R., Oppermann, M. L. R., Duncan, B. B., & Schmidt, M. I. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01606-x · Cited by 18
“In this regard, the routine use of an OGTT to screen for gestational diabetes mellitus (GDM) [7] in pregnancy is a great opportunity to identify high-risk subjects.”
From Mother to Child: Epigenetic Signatures of Hyperglycemia and Obesity during Pregnancy
Franzago, M., Borrelli, P., Di Nicola, M., Cavallo, P., D’Adamo, E., Di Tizio, L., Gazzolo, D., Stuppia, L., & Vitacolonna, E. (2024) · Nutrients · doi:10.3390/nu16203502 · Cited by 18
“GDM is defined as any degree of glucose intolerance that was first recognized during pregnancy but that was not clearly overt diabetes [8] and is often associated with obesity.”
BackgroundZhang, S., Ma, J., Ma, Y., Yi, J., Wang, B., Wang, H., Yang, Q., Zhang, K., Yan, X., Sun, D., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s492651 · Cited by 18
One-Hour Plasma Glucose Predicts the Progression From Normal Glucose Tolerance to Prediabetes
Abdul‐Ghani, M. A., Abu‐Farha, M., Abdul‐Ghani, T., Chavez-Velazquez, A., Merovci, A., DeFronzo, R. A., Al-Ajmi, F. A., Stern, M. P., & Al‐Mulla, F. (2025) · Diabetes Care · doi:10.2337/dc24-2832 · Cited by 18
Machine learning-based stratification of prediabetes and type 2 diabetes progression
Matboli, M., Khaled, A., Ahmed, M. F., Ahmed, M. Y., Khaled, R., Elmakromy, G. M., Ghani, A. M. A., ElShafei, M. M., Abdelhalim, M. R. M., & ElGwad, A. M. A. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01786-6 · Cited by 29
Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab
Mathieu, C., Sims, E. K., Chatenoud, L., James, E. A., Atkinson, M. A., & Herold, K. C. (2025) · Diabetes Care · doi:10.2337/dci25-0066 · Cited by 34
Barbieri, M., Prattichizzo, F., Grotta, R. L., Matacchione, G., Scisciola, L., Fontanella, R. A., Tortorella, G., Benedetti, R., Carafa, V., Marfella, R., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102405 · Cited by 18
“%) and incidence (8.3 / 1000 persons) in the elderly population (American Diabetes Association Professional Practice 2024), which currently seems to affect around 537 million individuals worldwide, half of whom, for various reasons including socio-economic factors, healthcare access, and lack of…”
BackgroundInfluentialChanoine, J., Thompson, D. M., & Lehman, A. (2024) · Diabetes · doi:10.2337/db24-0515 · Cited by 28
Mehta, S., Ryabets-Lienhard, A., Patel, N., Breidbart, E., Libman, I., Haller, M. J., Simmons, K. M., Sims, E. K., DiMeglio, L. A., Gitelman, S. E., et al. (2024) · Hormone Research in Paediatrics · doi:10.1159/000538775 · Cited by 17
“[15] de fi ning stage 2 as having two or more positive islet autoantibodies and dysglycemia by an oral glucose tolerance test (OGTT) or an alternative method if an OGTT is not available (Table 1).”
InfluentialGLP-1 agonists and exercise: the future of lifestyle prioritization
Codella, R., Senesi, P., & Luzi, L. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1720794 · Cited by 16
“…three-step approach – adapted from current World Health Organization (56), American College of Sports Medicine (57), American Diabetes Association (58), and European Association for the Study of Obesity (59) guidelines – is recommended: (1) introduce regular movement gradually, targeting 150…”
Association between cardiometabolic index and gestational diabetes mellitus: a cross-sectional study
Chen, M., Xiong, S., Zheng, J., Zhang, J., Ye, D., Xian, Y., Cao, Q., & Yan, K. (2024) · Endocrine · doi:10.1007/s12020-024-04045-2 · Cited by 19
“…and Pregnancy Study Groups Consensus Panel and the American Diabetes Association ’ s recommended one-step oral glucose tolerance test (OGTT) for identifying and evaluating hyperglycemic conditions during pregnancy, GDM is determined based on a fasting plasma glucose (FPG) ≥ 5.1 mmol/L [1, 20].”
InfluentialRuiz‐García, A., Serrano-Cumplido, A., Escobar, C., Arranz-Martínez, E., & Pallarés‐Carratalá, V. (2024) · Nutrients · doi:10.3390/nu16223948 · Cited by 24
Sakizlian, D. D. M., Boldeanu, L., Mitrea, A., Clenciu, D., Vladu, I. M., Plasiciuc, A. E. C., Șarla, A. V., Siloşi, I., Boldeanu, M. V., Assani, M.-Z., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136227 · Cited by 18
“…mmol/L; a random blood glucose level of 11.1 mmol/L or more; a OGTT blood glucose level exceeding 11.1 mmol/L; or the presence of hyperglycemic symptoms—such as polyuria, polydipsia, or significant weight loss—accompanied by a random glucose measurement indicative of a hyperglycemic crisis [59].”
InfluentialLin, Y., Zhang, Z., Zhong, J.-Q., Wang, Z., Peng, Y.-T., Lin, Y.-M., Zhang, H.-P., & Tian, J.-Q. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302155 · Cited by 19
A Real-World Study of the Effectiveness and Safety of Semaglutide for Weight Loss
Tzoulis, P., Batavanis, M., & Baldeweg, S. E. (2024) · Cureus · doi:10.7759/cureus.59558 · Cited by 30
“According to the American Diabetes Association criteria, the results were interpreted, and individuals were classified into the following groups: normoglycemia, prediabetes, and DM [14].”
MethodPredictive Factors for Urinary Tract Infections in Patients with Type 2 Diabetes
Sorescu, T., Cosnita, A., Braha, A., Timar, R. Z., Timar, B., Licker, M., Lazăr, S., Gaiţă, L., Albai, O., & Popescu, S. D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247628 · Cited by 25
Zhang, Y., Yang, X., & Wan, Q. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1537303 · Cited by 20
Dovč, K., Neuman, V., Gemulla, G., Cherubini, V., Alonso, G. T., Fritsch, M., Boettcher, C., de Beaufort, C. E., Holl, R. W., & de Bock, M. I. (2025) · Diabetes Care · doi:10.2337/dc24-2483 · Cited by 21
Zhu, L., Lv, T.-S., Song, S., Tan, Y., She, Y., Zhou, X., Yu, J., & Yan, Q. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01925-0 · Cited by 16
“…one or more of the following criteria: fasting blood glucose (FBG) ≥ 7.0 mmol/L, 2-hour post-load glucose during an oral glucose tolerance test (OGTT) ≥ 11.1 mmol/L, glycated hemoglobin (HbA1c) ≥ 6.5%, self-reported physician diagnosis, or current use of insulin or oral hypoglycemic agents [20].”
InfluentialLiang, J., Na, X., Meng, L., He, L., Shu, T., Fang, Y., Zhang, B., Zhao, Z., Guo, C., Li, J., et al. (2025) · MedComm · doi:10.1002/mco2.70245 · Cited by 20
“Diabetes is a group of metabolic disorders characterized by impaired glucose utilization and excessive production due to abnormal gluconeogenesis and glycogenolysis, leading to hyperglycemia [182].”
Cosma-Lăzuran, R., Leucuta, D., & Popoviciu, M. S. (2025) · Medicina · doi:10.3390/medicina61081433 · Cited by 15
“The diagnosis of type 2 diabetes mellitus was established based on medical history and biological criteria, in accordance with the guidelines of the American Diabetes Association (ADA, 2024) and current European recommendations [22].”
Knežević, S., Filippi-Arriaga, F., Belančić, A., Božina, T., Mršić‐Pelčić, J., & Vitezić, D. (2024) · Diabetology · doi:10.3390/diabetology5040031 · Cited by 20
“Type 2 diabetes (T2D) is a chronic complex disease characterized by hyperglycemia due to a non-autoimmune progressive loss of adequate β -cell insulin secretion, frequently an underlying element of insulin resistance and metabolic syndrome [113].”
The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function
Kantreva, K., Katsaounou, P. A., Saltiki, K., Trakada, G., Ntali, G., Stratigou, T., Tzanela, M., Ψαλτοπούλου, Θ., & Paschou, S. Α. (2024) · Endocrine · doi:10.1007/s12020-024-04033-6 · Cited by 18
“Type 2 Diabetes represents 90% of cases globally and is attributed to a combination of insulin resistance and inadequate insulin secretion by pancreatic beta cells [1].”
Cooper, Z., O’Shields, J., Ali, M. K., Chwastiak, L., & Johnson, L. C. M. (2024) · Diabetes Care · doi:10.2337/dc24-1334 · Cited by 51
Bhattacharya, S., Nagendra, L., Dutta, D., & Kamrul-Hasan, A. B. M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae878 · Cited by 21
Robertis, V. D., Stampalija, T., Abuhamad, A., Bosco, M., Chaoui, R., Formigoni, C., Moon‐Grady, A. J., Paladini, D., Pilu, G., Ramezzana, I. G., et al. (2025) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.29224 · Cited by 20
Age at Menopause and Development of Type 2 Diabetes in Korea
Ko, B., Jung, J.-H., Han, K., & Nam, G. E. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.55388 · Cited by 17
Yang, T., Guo, Y., Zhang, R., Zhong, J., Xu, Z., Liu, L., Peng, Z., Wang, F., Jiang, Y., Zhu, Y., et al. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.137364 · Cited by 16
Assani, M.-Z., Novac, M. B., Dijmărescu, A. L., Văduva, C.-C., Vladu, I. M., Clenciu, D., Mitrea, A., Ahrițculesei, R.-V., Stroe-Ionescu, A.-Ş., Assani, A.-D., et al. (2025) · Nutrients · doi:10.3390/nu17081339 · Cited by 20
“The shift from prediabetes to diabetes may occur slowly over many years, and once diabetes is identified, it cannot be reversed [4].”
Materials and System Design for Self‐Decision Bioelectronic Systems
Zeng, Q., Liu, H., Zhang, Y., Zheng, Y., Ding, X., Zhu, M., Shi, G., Wang, Y., Haick, H., & Zhang, M. (2026) · Advanced Materials · doi:10.1002/adma.202521164 · Cited by 31
Wang, B., Song, J., Zhang, Y., Cui, X., Huo, Z., Liu, W., Shi, W., Wan, S., Shi, D., Hong, L., et al. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.5c06613 · Cited by 18
Nazarpour, S., Simbar, M., Kiani, Z., Khalaji, N., Khorrami, M., & Naeiji, Z. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05960-4 · Cited by 28
“…diabetes is caused by autoimmune beta-cell destruction and usually leads to absolute insulin deficiency in adults, and type 2 diabetes is caused by a non-autoimmune progressive loss of adequate β-cell insulin secretion, frequently on the background of insulin resistance and metabolic syndrome [2].”
BackgroundAlshuweishi, Y., Abudawood, A., Alfayez, D. I., Almufarrih, A. A., Alanazi, F., Alshuweishi, F. A., & Almuqrin, A. (2024) · Healthcare · doi:10.3390/healthcare12151540 · Cited by 15
“According to hospital protocol, T2D was diagnosed either by a FBG level ≥ 126 mg/dL, a 2 h plasma glucose tolerance test of ≥ 200 mg/dL, or a HbA1c ≥ 6.5%, confirmed by a repeated test on a different day [35].”
MethodInfluentialAhrițculesei, R.-V., Boldeanu, L., Vladu, I. M., Clenciu, D., Mitrea, A., Cîmpeanu, R.-C., Mustață, M.-L., Siloşi, I., Boldeanu, M. V., & Vere, C. C. (2024) · Diagnostics · doi:10.3390/diagnostics14232661 · Cited by 15
Wang, J., Bi, C., Xi, H., & Wei, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1455534 · Cited by 13
Zou, M., & Shao, Z. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01467-w · Cited by 13
“…with diabetes were included, which can be classified based on anyone of the following criteria: (1) Fasting blood glucose levels ≥ 126 mg/dl (7mmol/L); (2) Random blood glucose levels ≥ 200 mg/ dl (11.1mmol/L); (3) Glycohemoglobin (HbA1c) levels ≥ 6.5%; (4) Self-reported diagnosed of diabetes [1].”
BackgroundInfluentialHeyborne, K., & Barbour, L. A. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005777 · Cited by 14
“The two options for universal screening supported by the American Diabetes Association 4 (fasting plasma glucose and glycosylated hemoglobin A 1C [Hb A 1C ]) at the first prenatal visit clearly meet these criteria, with Hb A 1C having the added advantage of not requiring a fasting state and…”
InfluentialButt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., Lam, C. S. P., BRINKER, M. D., Schloemer, P., Viswanathan, P., Lage, A. Z., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3649 · Cited by 17
Sun, R., Dai, H., Yao, C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c17712 · Cited by 16
Stamate, E., Culea-Florescu, A.-L., Miron, M., Piraianu, A. I., Dumitrascu, A. G., Fulga, I., Fulga, A., Patrascanu, O. S., Iancu, D., Ciobotaru, O. C., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113698 · Cited by 19
Edelman, S. V., Agardh, D., Cui, N., Hao, L., Wieloch, M., & Meneghini, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16454 · Cited by 21
Bulu, A., & Keser, S. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02007-x · Cited by 13
Exercise-induced inflammatory and metabolic adaptations in ageing: A meta-analytic compendium
Sheldon, R., Gan, A., Tasong, J., Yap, A., Ahmad, M., Júnior, P. R. H., Viswanathan, K., Setti, N. S. M., Jarman, O., Hoque-Uddin, S., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102974 · Cited by 17
Placental mitochondrial impairment and its association with maternal metabolic dysfunction
Grismaldo, A., Luévano‐Martínez, L. A., Reyes, M., García-Márquez, G. G., García‐Rivas, G., & Sobrevía, L. (2024) · The Journal of Physiology · doi:10.1113/jp285935 · Cited by 19
Yu, P., Yuan, H., Li, X., & Chen, H. (2024) · Endocrine · doi:10.1007/s12020-024-04043-4 · Cited by 18
“Diabetes was diagnosed based on the patient ’ s self-reported history or on the results of FPG, HbA1c, and symptoms according to American Diabetes Association criteria for the diagnosis of diabetes [15].”
Szczerbiński, Ł., Mandla, R., Schroeder, P. H., Porneala, B., Li, J. H., Florez, J. C., Mercader, J. M., Udler, M. S., & Manning, A. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-74730-9 · Cited by 21
Ahmed, S. M. I., Adnan, H., Khawaja, M. A., & Butler, A. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020753 · Cited by 17
“Ideally, the test is performed when the patient’s pretest FPG levels are between 100 and 125 mg/dL (5.6–6.9 mmol/L) [53,54].”
InfluentialAutophagy-lysosome pathway in insulin & glucagon homeostasis
Wu, Y., Wang, H., & Xu, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1541794 · Cited by 23
Ruseva, A., Dabbous, F. M., Ding, N., Fabricatore, A. N., Huse, S., Michalak, W., Nordstrom, B. L., Hartaigh, B. Ó., Zhao, Z., & Umashanker, D. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2482274 · Cited by 17
“[18].”
Felício, J. S., Araújo, M. A. M., de Lemos, G. N., Fernandes, I. J., Ruivo, L. O., Chambouleyron, E., Silva, L. D. S. D., Nunes, C. F., Paes, G. M. D. A., de Melo, F. T. C., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02666-z · Cited by 16
“All patients had a well-established clinical and laboratory diagnosis of T2DM [25].”
An overview on the mechanisms of encapsulation of polyphenols used to help fight diabetes mellitus
Adefegha, S. A., Ogundare, P. O., Oboh, G., Esatbeyoglu, T., & Papenbrock, J. (2025) · Discover Food · doi:10.1007/s44187-025-00455-x · Cited by 14
“…by increased resistance to insulin, a context denoting impaired glycemic responsiveness in specific cellular structures like muscles of the skeleton, the hepatocyte and fatty tissue, coupled alongside progressively abnormal production and release of insulin by cells that produces it [32, 33].”
Cesar, T. B., de Oliveira, M. R. M., Sandrim, V. C., Mendes, A., Bruder, R., de Oliveira, R. A. A., Sivieri, K., & Milenković, D. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1639901 · Cited by 18
“Additionally, its efficacy may diminish over time, often requiring the addition of other hypoglycemic agents to maintain glycemic control (3).”
Martin, S., Samuel, M., Stow, D., Ridsdale, A. M., Chen, J., Young, K., Green, H., Hattersley, A. T., L’Esperance, V., McKinley, T. J., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0556 · Cited by 18
“Even when guidelines, such as those set out by the American Diabetes Association(21), suggest the use of another test in addition to HbA1c, this may not mitigate against the problem of underdiagnosis.”
Triglycerides, Glucose Metabolism, and Type 2 Diabetes
Wang, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209910 · Cited by 26
“In contrast, type 2 diabetes arises from a non-autoimmune, progressive decline in β -cell insulin secretion, often occurring alongside insulin resistance and metabolic syndrome [34].”
He, D., Huang, Y., Ni, X., & Bao, Z. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03070-3 · Cited by 14
“Prior evidence indicates that HbA1c serves as a valid and reliable alternative marker for identifying hyperglycemia in non-fasting settings, thereby providing a more stable assessment of long-term glycemic status in this cohort [35, 36].”
Liu, Q. F., Li, Z., Li, S., Li, Y., Pan, H., & Tao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1770141 · Cited by 21
“Major diabetes associations have not yet recommended routine Vitamin D 3 supplementation for improving glycemic control in T1DM, primarily due to evidence heterogeneity and unde fi ned optimal dosing (129, 135).”
Qiao, Q., Liu, X., Xue, W., Chen, L., & Hou, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-62707-7 · Cited by 13
“…and previous NHANES studies: a fasting plasma glucose (FPG) concentration above 126 mg/dL (7.0 mmol/L), a 2 h plasma glucose concentration over 200 mg/dL (11.1 mmol/L), or a hemoglobin A1C (HbA1c) percentage of 6.5% or higher in an oral glucose tolerance test (OGTT) indicates the thresholds 14,15 .”
BackgroundInfluentialJ-shaped association of the triglyceride glucose-body mass index with new-onset diabetes
Qiao, Q., Liang, K., Wang, C., Wang, L., Yan, F., Chen, L., & Hou, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-64784-0 · Cited by 17
Szydełko, J., Czop, M., Petniak, A., Lenart-Lipińska, M., Kocki, J., Zapolski, T., & Matyjaszek‐Matuszek, B. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02374-0 · Cited by 15
“The diagnosis of T2DM was established according to the American Diabetes Association criteria [20].”
MethodJanota, O., Mantovani, M., Kwiendacz, H., Irlik, K., Bucci, T., Lam, S. H. M., Huang, B., Alam, U., Boriani, G., Hendel, M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02420-x · Cited by 15
Huang, J., Huang, Y., Lu, C.-H., Chuang, Y., Chien, H., Lin, C.-I., Chao, M., Chuang, H., Ho, C.-K., Wang, C.-L., et al. (2024) · Life · doi:10.3390/life14111399 · Cited by 24
“Diabetes was defined as a fasting glucose level of ≥ 126 mg/dL or self-reported use of insulin or antidiabetic agents [23].”
Skudder‐Hill, L., Sequeira, I. R., Ko, J., Poppitt, S. D., & Petrov, M. S. (2024) · Obesity · doi:10.1002/oby.24154 · Cited by 15
Wang, Q., Zhang, K., Zhang, X., Fu, J., Liu, F., Gao, Y., & Lin, R. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111943 · Cited by 17
Egan, A. M., Wood‐Wentz, C. M., Mohan, S., Bailey, K. R., & Vella, A. V. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.56067 · Cited by 14
Divergence in prediabetes guidelines – A global perspective
Pragati, G., & Pozzilli, P. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112142 · Cited by 13
Zhang, N., Wang, Y., Zhang, H., Fang, H., Li, X., Li, Z., Huan, Z., Zhang, Z., Wang, Y., Li, W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-01161-5 · Cited by 18
Vara-Luiz, F., Mendes, I., Palma, C., Mascarenhas, P., Simas, D., Gomes, P., Gonçalves, A. R., Simão, I. R., Teixeira, M., Lopes, S. R., et al. (2025) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848251343416 · Cited by 12
Calhoun, P. M., Spanbauer, C., Steck, A. K., Frohnert, B. I., Herman, M. A., Keymeulen, B., Veijola, R., Toppari, J., Desouter, A. K., Gorus, F., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06362-1 · Cited by 13
Huai, J., Chang, E.-E., Zhu, Y., Ma, W., Lv, T.-S., Sun, J., & Zhou, X. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1701406 · Cited by 18
Minor Papillotomy for Treatment of Idiopathic Acute Pancreatitis With Pancreas Divisum
Coté, G. A., Durkalski‐Mauldin, V. L., Fogel, E. L., Moffatt, D. C., Wang, A. Y., Lara, L. F., Tarnasky, P. R., Buxbaum, J. L., Dai, S.-C., Jonnalagadda, S. S., et al. (2026) · JAMA · doi:10.1001/jama.2025.23988 · Cited by 11
Rivas‐García, L., Quintana‐Navarro, G. M., Alcala-Diaz, J. F., Torres-Peña, J. D., Larriva, A. P. A.-D., Rangel-Zúñiga, O. A., López-Moreno, A., Malagón, M. M., Katsiki, N., Pérez‐Martínez, P., et al. (2024) · Nutrients · doi:10.3390/nu16081249 · Cited by 12
“All patients in the CORDIOPREV study without T2DM, according to the American Diabetes Association (ADA) diagnosis criteria [30] (i.e., fasting plasma glucose ≥ 126 mg/dL, 2-h plasma glucose in the 75 gr oral glucose tolerance test (OGTT) ≥ 200 mg/dL or plasma glycated hemoglobin (HbA1c) levels ≥ 6.5”
MethodInfluentialCui, D.-Y., Zhang, C., Chen, Y., Qian, G., Zheng, W.-X., Zhang, Z.-H., Zhang, Y. L., & Zhu, P. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02114-z · Cited by 12
“Diabetes status [17] was defined if the patients fulfilled at least one of the following criteria: (1) Fasting plasma glucose (FPG) ≥ 7 mmol/L, (2) HbA1c ≥ 6.5%, (3) 2-h plasma glucose during the OGTT ≥ 11.1 mmol/L, or (4) self-reported physician-diagnosed diabetes.”
InfluentialChianelli, M., Armellini, M., Carpentieri, M. S., Coccaro, C., Cuttica, C. M., Fusco, A., Marucci, S., Nelva, A., Nizzoli, M., Ponziani, M. C., et al. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303282327240507184902 · Cited by 15
Liu, Q., Qin, L., Liang, Y., Xu, M., Zhang, J., Mo, X., Tang, X., Lu, Y., Wang, X., Cao, J., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33044 · Cited by 11
“Base on the World Health Organization diagnostic criteria [13], T2DM was defined as:FPG ≥ 126mg/dl (7.0 mmol/l) or oral glucose tolerance test (OGTT) 2-h blood glucose value ≥ 200 mg/dl or HbA1c ≥ 6.5 % (48 mmol/mol) or a history of diabetes or taking antidiabetic medications.”
MethodInfluentialReal-Life Use of Automated Insulin Delivery in Individuals With Type 2 Diabetes
Fabris, C., & Kovatchev, B. P. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241274786 · Cited by 11
Bukhari, H. A., Afzal, M., Al-Abbasi, F. A., Sheikh, R. A., Alqurashi, M. M., Bawadood, A. S., Alzarea, S. I., Alamri, A. M., Sayyed, N., & Kazmi, I. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-71577-y · Cited by 18
Neira, G., Hernández‐Pardos, A. W., Becerril, S., Ramírez, B., Valentí, V., Moncada, R., Catalán, V., Gómez‐Ambrosi, J., Burrell, M. A., Silva, C., et al. (2024) · Obesity · doi:10.1002/oby.24132 · Cited by 13
Hopkins, R., Young, K., Thomas, N. J., Jones, A. G., Hattersley, A. T., Shields, B. M., Dennis, J., & McGovern, A. P. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16163 · Cited by 16
“12 There is a lack of studies providing evidence on whether oral diabetes therapies are effective and safe in the management of hyperglycaemia in type 3c diabetes.”
Zhang, M., Lin, H., & Xu, X. (2025) · BMC Public Health · doi:10.1186/s12889-025-21734-3 · Cited by 14
UNDERWOOD, P. C., Chirokas, K., Keels, J. N., Vimalananda, V. G., & Magny‐Normilus, C. (2025) · Journal of Health Equity · doi:10.1080/29944694.2024.2444002 · Cited by 12
Is it feasible for European laboratories to use SI units in reporting results?
Zaninotto, M., Agnello, L., Dukić, L., Šálek, T., Linko-Parvinen, A., Kalaria, T., & Vermeersch, P. (2025) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-0113 · Cited by 11
Universal screening for hyperglycemia in early pregnancy and the risk of adverse pregnancy outcomes
Shen, L., Zhang, S., Wen, J., Liu, J., Lin, X., Zhu, C., Cai, S., Xie, L., Wang, Z., & Chen, H. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07253-4 · Cited by 15
“The IADPSG [7] and the ADA [8] state that HbA1c 41–46 mmol/mol (5.9-6.4”
InfluentialCutaneous manifestations of diabetes mellitus: a narrative review
Abate, M. C. M. D. O., Aroucha, P. M. T., da Nóbrega, D. V. M., Rocha, I. P. M., Soares, S. D., Reis, A. A., Paliares, I. C., Giuffrida, F. M. A., Dib, S. A., Reis, A. F., et al. (2025) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2025rw1193 · Cited by 18
Ahrițculesei, R.-V., Boldeanu, L., Caragea, D. C., Vladu, I. M., Clenciu, D., Mitrea, A., Ungureanu, A. M., Văduva, C.-C., Dijmărescu, A. L., Popescu, A. I. S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083661 · Cited by 16
“These represent the initial four criteria for identifying PreDM [76].”
The critical elements of digital health in diabetes and cardiometabolic care
Shomali, M., Mora, P., Aleppo, G., Peeples, M., Kumbara, A., MacLeod, J., & Iyer, A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1469471 · Cited by 10
Self-citationFrom Prediction to Prevention: The Intricacies of Islet Autoantibodies in Type 1 Diabetes
Khine, A., & Quandt, Z. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01595-1 · Cited by 14
“Type 1 Diabetes (T1D) is an autoimmune disorder characterized by the progressive destruction of pancreatic beta cells, leading to insulin deficiency [1].”
Ma, C., Zhai, L., Huo, R., & Liu, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01896-1 · Cited by 17
“Diabetes was defined as FBG ≥ 7.0 mmol/L, HbA1c ≥ 6.5%, current use of antidiabetic medication, or self-reported history of diabetes [19, 21]; pre-diabetes was defined based on the diagnostic criteria of the ADA [22] as FBG ≥ 5.6 mmol/L and < 7.0 mmol/L, or HbA1c ≥ 5.7% and HbA1c < 6.5%.”
InfluentialTriglyceride–Glucose Index and New-Onset Type 2 Diabetes Mellitus in Middle-Aged Men
D’Elia, L., Rendina, D., Iacone, R., Strazzullo, P., & Galletti, F. (2025) · Metabolites · doi:10.3390/metabo15080537 · Cited by 17
“T2DM was defined according to standardised criteria (fasting blood glucose level ≥ 126 mg/dL or current anti-T2DM therapy) [28], both at baseline and follow-up examinations.”
Biosynthesized Silver Nanoparticles and Their Antidiabetic Potential
González-Garibay, A. S., Torres-González, O. R., Sánchez-Hernández, I. M., & Padilla‐Camberos, E. (2025) · Pharmaceuticals · doi:10.3390/ph18091412 · Cited by 13
“Gestational diabetes is diagnosed in the second or third trimester of pregnancy [1].”
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment
Koceva, A., Janež, A., & Jensterle, M. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102038 · Cited by 17
Dong, J., Huang, A., Zhang, Z., Yang, X., Sun, J., & Zhang, W. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1642243 · Cited by 10
Govindani, R. K., Sharma, A., Patel, N. P., Baradia, P., & Agrawal, A. (2024) · Cureus · doi:10.7759/cureus.63126 · Cited by 10
“In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same or different samples [17].”
BackgroundElsherif, I., Jammah, A. A., Ibrahim, A. R., Alawadi, F., Sadek, I. S., Rahman, A. M., Sharify, G. E., AlFeky, A., Aldossari, K. K., Roushdy, E., et al. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.06.003 · Cited by 11
ESRRA modulation by empagliflozin mitigates diabetic tubular injury via mitochondrial restoration
Yang, K., Liang, W., Hu, H., Zhang, Z., Hao, Y., Song, Z., Yang, L., Hu, J., Chen, Z., & Ding, G. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111308 · Cited by 11
Kawaguchi, Y., Hajika, Y., Ashida, N., Rinka, M., Hamai, C., Masumoto, K., Sawa, J., Hamazaki, K., & Kumeda, Y. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100318 · Cited by 12
“The inclusion criteria included a diagnosis of T2DM and DKD based on the American Diabetes Association Criteria [11,22] (based on the presence of UACRs ≥ 30 mg/gCr or reduced eGFR 60 mL/min/1.73 m 2 , or both, in the absence of signs or symptoms of other primary causes of kidney damage) at least…”
MethodInfluentialType 1 diabetes: immune pathology and novel therapeutic approaches
Ling, E. M., Lemos, J. R. N., Hirani, K., & von Herrath, M. (2024) · Diabetology International · doi:10.1007/s13340-024-00748-z · Cited by 14
Is there any association between vitamin D status and PCOS disease?
Zerrouki, D., Rami, I., Assarrar, I., Bouichrat, N., Rouf, S., & Latrech, H. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2024.2381501 · Cited by 12
“…syndrome was defined as having three or more of the following abnormalities: waist circumference in females greater than 88 cm; fasting serum glucose at least 110 mg/dl; fasting serum triglycerides at least 150 mg/dl; serum HDL-C less than 50 mg/dl; and blood pressure at least 130/85 mmHg [14].”
Zhou, X., Jiang, Y., Wang, Z., Wei, L., Zhang, H., Fang, C., Zhu, S., Du, Y., Su, R., Li, W., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01007-2 · Cited by 13
Won, S., Kim, H. J., Park, J. Y., Oh, K. J., Choi, S. H., Jang, H. C., & Moon, J. H. (2024) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e46 · Cited by 12
Catalán, V., Gómez‐Ambrosi, J., Ramírez, B., Unamuno, X., Becerril, S., Rodríguez, A., Baixauli, J., Reina, G., Sancho, A., Silva, C., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01008-1 · Cited by 13
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.